Chat with us, powered by LiveChat

EUROTOX Congress 2023

We were excited to attend EUROTOX 2023, which took place from 10 to 13 September in Slovenia!

Monday 11th September, 09:30 AM.

Scientist, Tasha Jones presented “Development of a network of adverse outcome pathways (AOPs) associating immunosuppression with cancer”. The poster itself outlines a preliminary network of AOPs linking MIEs leading to immunosuppression and resulting in carcinogenicity, which will aid in weight of evidence approaches for the assessment of pharmaceuticals adhering to the ICH S1B addendum, as well as other chemical classes.

Scientist, Victor Ude presented a poster titled “Contextualising genetic level knowledge using a network of developmental and reproductive toxicity (DART) adverse outcome pathways (AOPs)”. The poster describes our recent work on mapping transcriptomic data to our DART AOP network in order to contextualise genetic level data through mechanisms of toxicity. The overlap between published gene sets thought to be relevant to DART, and key events within our DART AOP network will be highlighted. In addition to this, an analysis of how we have used transcriptomics data to identify gaps for future AOP development will be discussed.

Principal Application Scientist, Grace Kocks presented a poster titled “How are pre-competitive data sharing initiatives in the pharmaceutical industry aiding in compiling nitrosamine risk assessments”. The poster details some of our ongoing data sharing initiatives related to nitrosamine impurity risk assessment. 

Monday 11th September, 12:00 – 13:00 PM.

We held our industry hosted session discussing; Using next generation carcinogenicity assessments to make confident human safety decisions, in room Povodni Mož 1. This talk was presented by Senior Application Scientist, Toni Rodgers and Principal Scientist, Alex Cayley.

Tuesday 12th September, 14:00 – 15:00 PM.

In Short Orals Session 2, Principal Scientist, Martyn Chilton presented “Combining an AOP-centred IATA and read across to derive a skin sensitisation point of departure for Next Generation Risk Assessment”. The talk used a case study to show how the skin sensitisation Adverse Outcome Pathway can be utilised within an Integrated Approach to Testing and Assessment to conclude on a chemicals’ sensitisation potential only using New Approach Methodologies. Read across also was leveraged to derive a point of departure for the chemical, which could be used within a Next Generation Risk Assessment.

Supporting the booth was Application Scientists, Jack Lupton and Rushali Shinde, and Business Partnerships, Lina Din and Pavlos Dimitriou.